113188-83-3

Basic information

• Product Name: 5-CHLORO-1H-INDOL-3-METHYLAMINE
• Synonyms: 5-CHLORO-1H-INDOL-3-METHYLAMINE;5-Chloro-1H-indole-3-methanamine;(5-Chloro-1H-indol-3-yl)MethanaMine;(5-Chloro-1H-indol-3-yl)
• CAS NO: 113188-83-3
• Molecular Formula: C9H9ClN2
• Molecular Weight: 180.63
• Mol File: 113188-83-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 369.8 °C at 760 mmHg
• Flash Point: 177.4 °C
• Appearance: /
• Density: 1.349
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 16.22±0.30(Predicted)
• CAS DataBase Reference: 5-CHLORO-1H-INDOL-3-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-1H-INDOL-3-METHYLAMINE(113188-83-3)
• EPA Substance Registry System: 5-CHLORO-1H-INDOL-3-METHYLAMINE(113188-83-3)

Safety Data

• Hazardous Substances Data: 113188-83-3(Hazardous Substances Data)

Usage

General Description

5-CHLORO-1H-INDOL-3-METHYLAMINE is a chemical compound with the formula C9H10ClN2. It is a derivative of indole and contains a chlorine atom and a methylamine functional group. 5-CHLORO-1H-INDOL-3-METHYLAMINE is used in the synthesis of various pharmaceuticals and agrochemicals, and it also exhibits potential biological activities. It has been investigated for its potential use as a monoamine oxidase inhibitor and a tryptamine receptor modulator. Additionally, 5-CHLORO-1H-INDOL-3-METHYLAMINE has been studied for its potential use in the treatment of cancer and neurodegenerative diseases. Overall, this compound is of interest for its diverse pharmacological properties and potential therapeutic applications.

Upstream product

• 1261024-31-0 5-chloro-1H-indole-3-carbaldehyde oxime 
• 827-01-0 5-chloro-1H-indole-3-carboxaldehyde 

Downstream Products

• 1597411-07-8 (4aS,9aS)-4a,6-dichloro-2-phenyl-9-tosyl-4,4a,9,9a-tetrahydro-[1,3]oxazino[6,5-b]indole 
• 1597410-11-1 C₁₆H₁₃ClN₂O 

Relevant articles and documents

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.

NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.